RecruitingDiabetes MellitusHypertension
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Eligible age
19+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Sponsor: Boryung Pharmaceutical Co., Ltd
You may qualify if…
- ✓ Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
- ✓ Those who voluntarily signed a written personal information agreement to participate in this clinical study.
- ✓ Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
You may not qualify if…
- ✕ Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
- ✕ Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
- ✕ Those who are expected to need insulin prescription during the study period
- ✕ Pregnant women, breast-feeding women
Source: ClinicalTrials.gov · NCT05970237 · last updated 2025-09-15